CA
AMED

Crewe Advisors’s Amedisys AMED Stock Holding History

Crewe Advisors’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1
Closed -$94 – 424
2023
Q3 		$94 Buy
+1
New +$92 ﹤0.01% 571
2022
Q4 		– Sell
-33
Closed -$3K – 1028
2022
Q3 		$3K Buy
33
+10
+43% +$1.19K ﹤0.01% 932
2022
Q2 		$2K Buy
+23
New +$2.94K ﹤0.01% 958

Other funds holding AMED

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Crewe Advisors's AMED Position: Q4 2023 in Review

Crewe Advisors sold out of Amedisys (AMED) in Q4 2023, closing a stake of 1 share — an estimated $94 sold.

Crewe Advisors first reported a position in AMED in Q2 2022 and held it in 3 quarters. The position peaked at $3K in Q3 2022. 287 funds tracked by Wall St. Rank hold AMED as of Q4 2023.

  • Crewe Advisors reported no remaining Amedisys position as of Q4 2023 after selling out during the quarter.
  • Crewe Advisors sold 1 Amedisys share in Q4 2023, an estimated $94.
  • Crewe Advisors first reported a position in Amedisys in Q2 2022 and held it in 3 quarters.
  • Crewe Advisors's Amedisys position peaked at $3K in Q3 2022.
  • 287 funds tracked by Wall St. Rank held Amedisys as of Q4 2023.

Based on Crewe Advisors's 13F filing for Q4 2023, filed 9 Feb 2024.